Beam Therapeutics, Inc. (BEAM)
26.41
+0.54
(+2.09%)
USD |
NASDAQ |
Nov 06, 16:00
26.72
+0.31
(+1.17%)
After-Hours: 20:00
Beam Therapeutics Cash from Investing (Quarterly) : 101.86M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 101.86M |
| June 30, 2026 | -9.875M |
| March 31, 2026 | 25.27M |
| December 31, 2025 | 108.41M |
| September 30, 2025 | 65.66M |
| June 30, 2025 | -170.41M |
| March 31, 2025 | -125.09M |
| December 31, 2024 | 126.28M |
| September 30, 2024 | 24.70M |
| June 30, 2024 | 87.49M |
| March 31, 2024 | -53.46M |
| December 31, 2023 | 98.10M |
| September 30, 2023 | -10.23M |
| June 30, 2023 | -41.48M |
| March 31, 2023 | 25.45M |
| December 31, 2022 | 113.44M |
| Date | Value |
|---|---|
| September 30, 2022 | -36.17M |
| June 30, 2022 | -1.262M |
| March 31, 2022 | -537.34M |
| December 31, 2021 | -77.50M |
| September 30, 2021 | 76.12M |
| June 30, 2021 | -13.14M |
| March 31, 2021 | -279.63M |
| December 31, 2020 | -81.43M |
| September 30, 2020 | 35.23M |
| June 30, 2020 | 22.87M |
| March 31, 2020 | -76.79M |
| December 31, 2019 | 16.56M |
| September 30, 2019 | 14.21M |
| June 30, 2019 | -95.08M |
| March 31, 2019 | -2.354M |
| December 31, 2018 | -11.22M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | -141.57M |
| Twist Bioscience Corp. | -10.20M |
| Prime Medicine, Inc. | 24.03M |
| Sarepta Therapeutics, Inc. | -93.37M |
| Q32 Bio, Inc. | -0.052M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -110.75M |
| Cash from Financing (Quarterly) | 2.327M |
| Free Cash Flow | -398.24M |
| Free Cash Flow Per Share (Quarterly) | -1.069 |
| Free Cash Flow to Equity (Quarterly) | -108.47M |
| Free Cash Flow to Firm (Quarterly) | -111.96M |
| Free Cash Flow Yield | -14.46% |